

## REMARKS/ARGUMENTS

### Restriction Requirement

The Examiner has required restriction to one of the following inventions:

- |            |  |
|------------|--|
| Group I    | Claims 1-8, drawn to an isolated nucleic acids.                                      |
| Group II   | Claims 9-11, drawn to a polypeptide.   |
| Group III  | Claims 12-13, drawn to an antibody.  |
| Group IV   | Claims 14-17, drawn to a composition of matter.                                      |
| Group V    | Claims 18-19, drawn to a method of treating a B-cell related disease.                |
| Group VI   | Claim 20, drawn to a method of detecting a polypeptide.                              |
| Group VII  | Claims 21 and 28, drawn to a method of diagnosis based on the gene expression level. |
| Group VIII | Claim 22, drawn to a method of diagnosis based on the use of antibodies.             |
| Group IX   | Claim 23, drawn to a method of detection of an activity inhibitor of a protein.      |
| Group X    | Claims 24 and 25, drawn to a method of detection of a gene repressor                 |
| Group XI   | Claim 26, drawn to a method of detection of an agonist analogous of a protein.       |
| Group XII  | Claim 27, drawn to a method of stimulation of a B cell response.                     |

The Examiner has also required that a SEQ ID NO be elected.

Applicants elect Group I, Claims 1-8, drawn to an isolated nucleic acid. Applicants further select SEQ ID NO:17 for the elected claims.

Applicants have canceled Claims 9-28, which are directed to non-elected inventions. Claim 1 has also been canceled as it is not pertinent to the selected SEQ ID NO:17. Claims 2 and 3 have been amended to delete the non-selected SEQ ID NOs. Claim 4 has been amended to be dependent from Claim 2. The amendments are fully supported by the specification and claims originally filed and do not introduce any new matter. Applicants reserve the right to pursue the canceled subject matters in a continuation, continuation-in-part, or divisional application. Claims 2-8 are pending after the amendments. Applicants respectfully request that the Examiner consider the amendments.

### CONCLUSION


In conclusion, the present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited. Should there be any further issues outstanding, the Examiner is invited to contact the undersigned agent at the telephone number shown below.

Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (referencing Attorney's Docket No. 39766-0262 R1).

Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully Submitted,

Date: November 27, 2007

By:   
Panpan Gao (Reg. No. 43,626)

**HELLER EHRMAN LLP**  
275 Middlefield Road  
Menlo Park, California 94025  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

SV 2318262 v1  
(39766.0262)